Company / Return on Equity (ROE)
Lexaria Bioscience Corp. Return on Equity (ROE) History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-193.8%
FY2025
5-year range
-238.8% / -30.4%
FY2021-FY2025
Trend
-133.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Lexaria Bioscience Corp. reports negative total equity of -193.8% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-193.8% in FY2025 with a 10-year CAGR of +8.0%.
Improved from -238.8% to -193.8% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -163.5pp
- 5-Year Change
- -19.3pp
- 10-Year Change
- +8.0pp
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 133.7% year-over-year.
- Peak return on equity (roe) was recorded in FY2022.
- Lowest return on equity (roe) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -193.8% | -133.7% |
| FY2024 | -82.9% | +65.3% |
| FY2023 | -238.8% | -686.6% |
| FY2022 | -30.4% | +81.5% |
| FY2021 | -164.5% | +5.7% |
| FY2020 | -174.5% | +26.9% |
| FY2019 | -238.8% | - |
| FY2017 | - | - |
| FY2016 | - | - |
| FY2015 | -201.9% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026